Sold as Nyvepria. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pegfilgrastim-Apgf (sold as Nyvepria), first approved Jun 10, 2020, with 0 new uses approved and 0 published complete response letters.
| Nyvepria | Part D | $25.3M | +147% | 1,830 |
| Nyvepria | Part B | $13.7M | +45% | 2,697 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasFollicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type · City of Hope Medical Center | Phase 1 | Recruiting | Dec 12, 2025 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 · University of Washington | Phase 2 | Recruiting | Nov 4, 2025 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma · National Cancer Institute (NCI) | Phase 3 | Active, not recruiting | Feb 18, 2021 |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTCentral Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma · Children's Oncology Group | Phase 2 | Recruiting | Dec 24, 2020 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRenal Pelvis and Ureter Urothelial Carcinoma · National Cancer Institute (NCI) | Phase 2 / Phase 3 | Recruiting | Nov 16, 2020 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma · Mayo Clinic | Phase 1 | Active, not recruiting | Mar 27, 2020 |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaAnn Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · National Cancer Institute (NCI) | Phase 3 | Active, not recruiting | Apr 9, 2019 |
| Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasAIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma · National Cancer Institute (NCI) | Phase 1 | Active, not recruiting | Jul 18, 2017 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 10, 2020 | NyvepriaBLA 761111 · New active ingredient | Hospira Inc | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
